531 related articles for article (PubMed ID: 25842168)
1. Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.
Califano R; Abidin A; Tariq NU; Economopoulou P; Metro G; Mountzios G
Cancer Treat Rev; 2015 May; 41(5):401-11. PubMed ID: 25842168
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy for NSCLC with driver mutations.
Minuti G; D'Incecco A; Cappuzzo F
Expert Opin Biol Ther; 2013 Oct; 13(10):1401-12. PubMed ID: 23930754
[TBL] [Abstract][Full Text] [Related]
3. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F
Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058
[TBL] [Abstract][Full Text] [Related]
4. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
5. Rare mutations in non-small-cell lung cancer.
D'Arcangelo M; D'Incecco A; Cappuzzo F
Future Oncol; 2013 May; 9(5):699-711. PubMed ID: 23647298
[TBL] [Abstract][Full Text] [Related]
6. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
7. Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.
Rebuzzi SE; Zullo L; Rossi G; Grassi M; Murianni V; Tagliamento M; Prelaj A; Coco S; Longo L; Dal Bello MG; Alama A; Dellepiane C; Bennicelli E; Malapelle U; Genova C
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807876
[TBL] [Abstract][Full Text] [Related]
8. ALK inhibitors and advanced non-small cell lung cancer (review).
Rossi A; Maione P; Sacco PC; Sgambato A; Casaluce F; Ferrara ML; Palazzolo G; Ciardiello F; Gridelli C
Int J Oncol; 2014 Aug; 45(2):499-508. PubMed ID: 24889366
[TBL] [Abstract][Full Text] [Related]
9. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
[TBL] [Abstract][Full Text] [Related]
10. The impact of genomic changes on treatment of lung cancer.
Cardarella S; Johnson BE
Am J Respir Crit Care Med; 2013 Oct; 188(7):770-5. PubMed ID: 23841470
[TBL] [Abstract][Full Text] [Related]
11. Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challenge.
Su C; Zhou F; Shen J; Zhao J; O'Brien M
Eur J Cancer; 2017 Sep; 83():266-278. PubMed ID: 28763691
[TBL] [Abstract][Full Text] [Related]
12. Novel targets in non-small cell lung cancer: ROS1 and RET fusions.
Gainor JF; Shaw AT
Oncologist; 2013; 18(7):865-75. PubMed ID: 23814043
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
Benjamin DJ; Haslam A; Gill J; Prasad V
Cancer Med; 2022 Sep; 11(18):3417-3424. PubMed ID: 35315222
[TBL] [Abstract][Full Text] [Related]
14. Emerging protein kinase inhibitors for non-small cell lung cancer.
Liu SV; Subramaniam D; Cyriac GC; Abdul-Khalek FJ; Giaccone G
Expert Opin Emerg Drugs; 2014 Mar; 19(1):51-65. PubMed ID: 24354593
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives.
Genova C; Rossi G; Tagliamento M; Rijavec E; Biello F; Cerbone L; Zullo L; Grossi F
Expert Rev Respir Med; 2020 Apr; 14(4):367-383. PubMed ID: 31917616
[No Abstract] [Full Text] [Related]
16. Emerging targeted therapies in non-small cell lung cancer.
Khanal N; Ganti AK
Expert Rev Anticancer Ther; 2016; 16(2):177-87. PubMed ID: 26618563
[TBL] [Abstract][Full Text] [Related]
17. [Molecular profiling of non-small cell lung cancer].
Gibault L; Cazes A; Narjoz C; Blons H
Rev Pneumol Clin; 2014; 70(1-2):47-62. PubMed ID: 24566035
[TBL] [Abstract][Full Text] [Related]
18. Molecular Targets Beyond the Big 3.
Reckamp KL
Thorac Surg Clin; 2020 May; 30(2):157-164. PubMed ID: 32327174
[TBL] [Abstract][Full Text] [Related]
19. Update on systemic therapy of advanced non-small-cell lung cancer.
Cufer T; Knez L
Expert Rev Anticancer Ther; 2014 Oct; 14(10):1189-203. PubMed ID: 25098682
[TBL] [Abstract][Full Text] [Related]
20. [Driver genes expression and clinical characteristics of targeted therapy in non-small cell lung cancer in Yunnan-Kweichow Plateau].
Lin YP; Li Q; Ma LY; Liu X; Dai M; Wang XX; Li HS; Liu JX; Shen ZH; Guo YJ; Du YX; Yang RJ; Huang YC; Zhou YC
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):735-740. PubMed ID: 32988155
[No Abstract] [Full Text] [Related]
[Next] [New Search]